Top Markets
Coin of the day
BRIM Biotechnology, Inc. BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc.

6885
Rank in Stocks #22414
BRIM Biotechnology, Inc., a clinical-stage firm, specializes in developing... BRIM Biotechnology, Inc., a clinical-stage firm, specializes in developing innovative regenerative therapies to address both ophthalmic and degenerative joint conditions. Leading its pipeline is BRM 421, a topical ophthalmic solution designed to treat moderate-to-severe dry eye syndrome, which has successfully completed a Phase 2 clinical trial in the United States. The company's development efforts also encompass BRM 423, currently in Phase 1 clinical trials for severe corneal damage; BRM 424, also in Phase 1, targeting neurotrophic keratitis; and BRM 521, which aims to alleviate and repair tissue damage caused by osteoarthritis. Founded in 2013, BRIM Biotechnology is headquartered in Taipei, Taiwan.
Share Price
$0.66936954
Last synced: 2026-07-28
Market Cap
$89.04M
Change (1 day)
0.00%
Change (1 year)
-40.10%
Country
TW
Trade BRIM Biotechnology, Inc. (6885)

Category

Earnings for BRIM Biotechnology, Inc. (6885)
Earnings in 2026 TTM: 0
According to BRIM Biotechnology, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for BRIM Biotechnology, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH